Aura Biosciences is a clinical-stage biotechnology company using its targeted oncology platform to develop a potential new standard of care across various cancer indications, with an initial focus on ocular and urologic oncology. Co.'s proprietary platform enables the targeting of a range of solid tumors using Virus-Like Particles that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDC). AU-011, Co.'s VDC candidate, is being developed for the first line treatment of primary choroidal melanoma. In addition, Co. is developing AU-011 for the treatment of non-muscle invasive bladder cancer. The AURA stock yearly return is shown above.
The yearly return on the AURA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AURA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|